ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå ±Ô¸ð, Á¡À¯À², µ¿Ç⠺м® ¸®Æ÷Æ® : ±â¼úº°, ¿ëµµº°, ÃÖÁ¾ ¿ëµµº°, ¸ð´Þ¸®Æ¼º°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2024-2030³â)
AI In Medical Imaging Market Size, Share & Trends Analysis Report By Technology (Deep Learning, NLP), By Application (Neurology, Orthopedics), By End Use (Hospitals, Diagnostic Centers), By Modalities, By Region, And Segment Forecasts, 2024 - 2030
»óǰÄÚµå
:
1529744
¸®¼Ä¡»ç
:
Grand View Research, Inc.
¹ßÇàÀÏ
:
2024³â 07¿ù
ÆäÀÌÁö Á¤º¸
:
¿µ¹® 90 Pages
¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
ÀÇ·á ¿µ»ó¿ë AI ½ÃÀåÀÇ ¼ºÀå°ú µ¿Çâ :
Grand View ResearchÀÇ ÃֽЏ®Æ÷Æ®¿¡ µû¸£¸é ¼¼°èÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 81¾ï 8,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ Àü¸ÁÀÔ´Ï´Ù.
ÀÌ ½ÃÀåÀº °í·ÉÈ Ãß¼¼¿Í Á¤ºÎ ¹× ¹Î°£ ±â¾÷ÀÇ ÇコÄÉ¾î »ýŰ迡 ´ëÇÑ ÅõÀÚ Áõ°¡·Î ÀÎÇØ 2024-2030³â ¿¬Æò±Õ 34.8%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ ½ÅÈï ±¹°¡µéÀº ÀÌ·¯ÇÑ Àα¸ Åë°èÇÐÀû µµÀü¿¡ ´ëÀÀÇϱâ À§ÇØ »ç¶÷µé¿¡°Ô Àú·ÅÇϰí Áøº¸µÈ ÀÇ·á ½Ã½ºÅÛ¿¡ ´ëÇÑ Á¢±Ù¼ºÀ» Á¦°øÇϱâ À§ÇØ ÅõÀÚÇϰí ÀÖÀ¸¸ç, ÀÌ´Â ±Ã±ØÀûÀ¸·Î ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ¿¢½º·¹ÀÌ ¿µ»ó ±â¼úÀº °ñÀý, °¨¿°, ´Ù¾çÇÑ ¾Ç¼º Á¾¾ç, °üÀý¿° µî ´Ù¾çÇÑ Áúº´À» ½Äº°ÇÏ´Â µ¥ Ȱ¿ëµÇ°í ÀÖ½À´Ï´Ù. °á°úÀûÀ¸·Î ÀÌ·¯ÇÑ Áúº´ÀÇ ¹ßº´·ü Áõ°¡´Â ½ÃÀå ¼ºÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÄ¥ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
COVID-19´Â ´Ü½Ã°£¿¡ Áß¿äÇÑ Áø´ÜÀ» Á¦°øÇϹǷΠ´ë´Ù¼öÀÇ ÀÇ·á Àü¹®°¡µéÀÌ °¡Àå ³Î¸® º¸±ÞµÈ COVID-19 ¼±º°°Ë»ç ¹æ¹ý Áß Çϳª·Î ¿µ»óÁø´ÜÀ» ¼±ÅÃÇßÀ¸¹Ç·Î ½ÃÀå¿¡ ±àÁ¤ÀûÀÎ ¿µÇâÀ» ¹ÌÃÆ½À´Ï´Ù. ¿µ»ó µ¥ÀÌÅͼ¼Æ®´Â ¹ÙÀÌ·¯½º¿Í ´Ù¾çÇÑ °èÃþÀÇ »ç¶÷µé¿¡°Ô ¹ÌÄ¡´Â ¿µÇâÀ» Á¶»çÇÏ´Â µ¥ »ç¿ëµÇ¾ú½À´Ï´Ù. °ÅÀÇ ¸ðµç ÀÇ·á ±â°üÀÌ COVID-19ÀÇ °ü¸®¸¦ °³¼±Çϰí È®»êÀ» ¾ïÁ¦Çϱâ À§ÇØ ³ë·ÂÇϰí ÀÖÀ¸¹Ç·Î ¸¹Àº º´¿øÀÌ ÀÇ·á ¿µ»ó ¹× ¿µ»ó ºÐ¼® ±â¼ú¿¡ ÀÇÁ¸ÇÏ¿© ¹ÙÀÌ·¯½ºÀÇ ½Äº° ¹× Á¦¾î¸¦ °³¼±Çϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 6¿ù Ç÷θ®´ÙÀÇ ÅÆÆÄ Á¾ÇÕº´¿øÀº AI ±â¹Ý ±â¼úÀ» µµÀÔÇÏ¿© Á÷¿ø ¹× ´Ù¸¥ ȯÀÚ¿Í Á¢ÃËÇϱâ Àü¿¡ COVID-19 °¨¿° ¿©ºÎ¸¦ È®ÀÎÇß½À´Ï´Ù.
ÀΰøÁö´É(AI) ±â¼úÀÌ Á¦°øÇÏ´Â ÀÌÁ¡°ú ÀÇ·á ºÐ¾ß¿¡¼ÀÇ Àû¿ë¿¡ ´ëÇÑ ÀνÄÀÌ ³ô¾ÆÁö¸é¼ ÇコÄÉ¾î ½ÃÀå¿¡¼ AI ±â¹Ý ¼Ö·ç¼Ç, Á¦Ç° ¹× ¼ºñ½º äÅÃÀÌ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ ÇコÄÉ¾î »ê¾÷À» À§ÇÑ Ã·´Ü AI ±â¹Ý ¿ëµµÀ» °³¹ßÇϱâ À§ÇØ ÀϺΠÁÖ¿ä ÇコÄÉ¾î ±â¾÷Àº °í°´¿¡°Ô ÃÖ÷´Ü ¼Ö·ç¼ÇÀ» Á¦°øÇÏ°í °æÀïÀûÀÎ ½ÃÀå ȯ°æ¿¡¼ ÀÔÁö¸¦ °ÈÇϱâ À§ÇØ Á¦ÈÞ, M&A, ¼±µµÀûÀÎ AI ±â¼ú °ø±Þ¾÷ü¿ÍÀÇ ÆÄÆ®³Ê½Ê µî ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ´Ù¾çÇÑ Àü·«À» äÅÃÇϰí ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î 2020³â 6¿ù ÀÎÅÚÀº ¸¶¸®ÄÚÆÄ Ä«¿îƼ Ä¿¹Â´ÏƼ Ä®¸®Áö Áö±¸¿Í Á¦ÈÞÇÏ¿© ºÏ¹Ì ÃÖÃÊÀÇ ÀΰøÁö´É ÁØÇлç ÇÐÀ§¸¦ µµÀÔÇÑ´Ù°í ¹ßÇ¥Çß½À´Ï´Ù. ÀÌ ±¸»óÀº ¾Ö¸®Á¶³ª ÁÖ »ó¹«ºÎ·ÎºÎÅÍ 10¸¸ ´Þ·¯ÀÇ ³ëµ¿·Â º¸Á¶±ÝÀ» Áö¿ø¹Þ°Ô µË´Ï´Ù. À̹ø Á¦ÈÞ¸¦ ÅëÇØ ¸¹Àº ÇлýµéÀÌ ÀÚµ¿Â÷, ±â¼ú, ÀÇ·á, Ç×°ø¿ìÁÖ »ê¾÷À¸·Î Ãë¾÷ÇÒ ¼ö ÀÖ°Ô µÇ¾î ¸¹Àº ÇлýµéÀÌ ÇýÅÃÀ» ¹ÞÀ» ¼ö ÀÖÀ» °ÍÀ¸·Î ±â´ëµË´Ï´Ù.
ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå º¸°í¼ ÇÏÀ̶óÀÌÆ®
- ±â¼úº°·Î´Â µö·¯´× ºÎ¹®ÀÌ º¹ÀâÇÑ ÀÇ·á ¿µ»óÀ» ºÐ¼®Çϰí Á¤È®ÇÑ Áø´ÜÀ» Á¦°øÇÏ´Â ¶Ù¾î³ ´É·ÂÀ¸·Î 2023³â 57.94%ÀÇ °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ¿ëµµº°·Î º¸¸é ½Å°æÇÐ ºÐ¾ß°¡ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù. ÀÌ´Â ´õ ³ªÀº ȯÀÚ Ä¡·á¸¦ Á¦°øÇÏ°í ´õ ³ôÀº Á¤È®µµ¿Í È¿À²¼ºÀ» Á¦°øÇϱâ À§ÇØ ½Å°æÇÐ ºÐ¾ß¿¡¼ AIÀÇ »ç¿ëÀÌ Áõ°¡Çϰí Àֱ⠶§¹®ÀÔ´Ï´Ù.
- CT ½ºÄµ ºÎ¹®Àº ½ÅüÀÇ »ó¼¼ÇÑ ´Ü¸é À̹ÌÁö¸¦ Á¦°øÇÏ´Â ´É·ÂÀ¸·Î ÀÎÇØ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
- º´¿ø ºÎ¹®Àº 2023³â °¡Àå Å« Á¡À¯À²À» Â÷ÁöÇÏ°í ¿¹Ãø ±â°£ Áß °¡Àå ºü¸¥ CAGR·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
- ºÏ¹Ì ÀÇ·á ¿µ»ó AI ½ÃÀåÀº 2023³â ¼¼°è ¾÷°è¸¦ Áö¹èÇϸç 2023³â 43.00% ÀÌ»óÀÇ °¡Àå Å« ¸ÅÃâ Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
¸ñÂ÷
Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§
Á¦2Àå °³¿ä
Á¦3Àå ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§
- ½ÃÀå °èÅë Àü¸Á
- ¸ð½ÃÀå Àü¸Á
- °ü·Ã/ºÎ¼ö ½ÃÀå Àü¸Á
- ½ÃÀå ¿ªÇÐ
- ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ ºÐ¼®
- ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ ºÐ¼®
- ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå ºÐ¼® Åø
- ¾÷°è ºÐ¼® - PorterÀÇ »ê¾÷ ºÐ¼®
- PESTEL ºÐ¼®
- COVID-19ÀÇ ¿µÇâ
Á¦4Àå ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ±â¼úº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ±â¼úº° ½ÃÀå Á¡À¯À², 2023³â°ú 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ±â¼úº° Àü¸Á
- µö·¯´×
- ÀÚ¿¬¾ð¾îó¸®(NLP)
- ±âŸ
Á¦5Àå ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ¿ëµµº° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ¿ëµµº° Àü¸Á
- ½Å°æÇÐ
- È£Èí±â¿Í Æó
- ½ÉÀ庴ÇÐ
- À¯¹æ¾Ï °ËÁø
- Á¤Çü¿Ü°ú
- ±âŸ
Á¦6Àå ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ¸ð´Þ¸®Æ¼º° ÃßÁ¤¡¤µ¿Ç⠺м®
- ¸ð´Þ¸®Æ¼º° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ¸ð´Þ¸®Æ¼º° Àü¸Á
- CT ½ºÄµ
- MRI
- X¼±
- ÃÊÀ½ÆÄ
- ÇÙÀ̹Ì¡
Á¦7Àå ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ÃÖÁ¾ ¿ëµµº° ÃßÁ¤¡¤µ¿Ç⠺м®
- ÃÖÁ¾ ¿ëµµº° ½ÃÀå Á¡À¯À², 2023³â ¹× 2030³â
- ºÎ¹® ´ë½Ãº¸µå
- ¼¼°èÀÇ ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : ÃÖÁ¾ ¿ëµµº° Àü¸Á
- º´¿ø
- ¿µ»ó Áø´Ü ¼¾ÅÍ
- ±âŸ
Á¦8Àå ÀÇ·á ¿µ»ó¿ë AI ½ÃÀå : Áö¿ªº° ÃßÁ¤¡¤µ¿Ç⠺м®, ±â¼úº°, ¿ëµµº°, ¸ð´Þ¸®Æ¼º°, ÃÖÁ¾ ¿ëµµº°, AIžÀç ÀÇ·á ¿µ»ó¿ë AI
- Áö¿ªº° ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â ¹× 2030³â
- Áö¿ªº° ½ÃÀå ´ë½Ãº¸µå
- ¼¼°èÀÇ Áö¿ª ½ÃÀå ½º³À¼ô
- ½ÃÀå ±Ô¸ð, ¿¹Ãø µ¿Ç⠺м®, 2018-2030³â :
- ºÏ¹Ì
- À¯·´
- ¾Æ½Ã¾ÆÅÂÆò¾ç
- ¶óƾ¾Æ¸Þ¸®Ä«
- Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«
Á¦9Àå °æÀï ±¸µµ
- ÁÖ¿ä ½ÃÀå Âü¿© ±â¾÷¿¡ ÀÇÇÑ ÃÖ±Ù µ¿Çâ°ú ¿µÇ⠺м®
- ±â¾÷/°æÀï ºÐ·ù
- À̳뺣ÀÌÅÍ
- ÁÖ¿ä ÆÇ¸Å ´ë¸®Á¡ ¹× ä³Î ÆÄÆ®³Ê ¸®½ºÆ®
- ÁÖ¿ä °í°´
- ÁÖ¿ä ±â¾÷ÀÇ ½ÃÀå Á¡À¯À² ºÐ¼®, 2023³â
- GE Healthcare
- Microsoft
- Digital Diagnostics Inc.
- Tempus
- Butterfly Network Inc.
- Advanced Micro Devices, Inc.
- Heartflow Inc.
- Enlitic, Inc.
- Canon Medical Systems, Inc.
- Viz.ai, Inc.
- EchoNous, Inc.
- HeartVista, Inc.
- Exo Imaging, Inc.
- NANO-X IMAGING LTD
KSA
¿µ¹® ¸ñÂ÷
AI In Medical Imaging Market Growth & Trends:
The global AI in medical imaging market size is expected to reach USD 8.18 billion by 2030, based on a new report by Grand View Research, Inc. The market is expected to grow at a CAGR of 34.8% from 2024 to 2030 owing to the growing aging population and increased investment in the healthcare ecosystem by government and private players. Moreover, developed countries have been investing in offering people access to inexpensive and advanced healthcare systems in response to this demographic challenge, ultimately boosting the market growth. Additionally, X-ray imaging technology is utilized to identify a variety of disorders, including fractures, infections, various malignancies, and arthritis. As a result, the rise in the incidence rate of these diseases is expected to have a positive impact on the market growth.
COVID-19 had a positive impact on the market as the majority of medical professionals chose imaging as one of the most popular COVID-19 screening modalities as it provided critical diagnostic in a short time. The entire set of imaging data has been used to research the virus and its effect on people of various demographics. Many hospitals have resorted to medical imaging and image analytics techniques to improve the identification and control of the virus as nearly every healthcare organization is working to manage COVID-19 better and limit its spread. For instance, in June 2020, a hospital in Florida, the Tampa General Hospital employed AI-driven technology to check people for COVID-19 before they interacted with staff members and other patients.
The rising awareness regarding the benefits offered by Artificial Intelligence (AI) technologies and their application in the medical field has led to increased adoption of AI-based solutions, products, and services in the healthcare market. Moreover, to develop advanced AI-based applications for the healthcare industry, several leading healthcare companies are adopting different strategies such as collaborations, mergers & acquisitions, and partnerships with top AI technology vendors to provide cutting-edge solutions to their clients and strengthen their position in this competitive market environment. For instance, in June 2020, Intel announced its partnership with Maricopa County Community College District to introduce the first artificial intelligence associate degree in the North American region. The initiative will also be supported by a USD 100,000 workforce grant from the Arizona Commerce Authority. A number of students are expected to benefit from this partnership as it enables students to pursue employment in the automotive, technology, healthcare, and aerospace industries.
AI In Medical Imaging Market Report Highlights:
- Based on technology, the deep learning segment held the largest share of 57.94% in 2023 owing to its superior ability to analyze complex medical images and provide accurate diagnostics.
- Based on application, the neurology segment held the largest market share in 2023 owing to the increased use of AI in neurology, as it provides better patient care and enables higher accuracy and high efficiency.
- The CT scan segment held the largest market share in 2023 due to their ability to provide detailed cross-sectional images of the body making them indispensable in medical diagnostics.
- The hospitals segment dominated the market with the largest share in 2023 and is expected to grow at the fastest CAGR of over the forecast period.
- The AI in medical imaging market in North America dominated the global industry in 2023 and accounted for the largest revenue share of over 43.00% in 2023.
Table of Contents
Chapter 1. Methodology and Scope
- 1.1. Market Segmentation & Scope
- 1.1.1. Technology
- 1.1.2. Application
- 1.1.3. Modalities
- 1.1.4. End Use
- 1.1.5. AI-Powered AI in Medical Imaging
- 1.1.6. Regional scope
- 1.1.7. Estimates and forecast timeline.
- 1.2. Research Methodology
- 1.3. Information Procurement
- 1.3.1. Purchased database
- 1.3.2. GVR's internal database
- 1.3.3. Secondary sources
- 1.3.4. Primary research
- 1.3.5. Details of primary research
- 1.4. Information or Data Analysis
- 1.4.1. Data analysis models
- 1.5. Market Formulation & Validation
- 1.6. Model Details
- 1.6.1. Commodity flow analysis (Model 1)
- 1.6.2. Approach 1: Commodity flow approach
- 1.6.3. Volume price analysis (Model 2)
- 1.6.4. Approach 2: Volume price analysis
- 1.7. List of Secondary Sources
- 1.8. List of Primary Sources
- 1.9. Objectives
Chapter 2. Executive Summary
- 2.1. Market Outlook
- 2.2. Segment Outlook
- 2.2.1. Technology outlook
- 2.2.2. Application outlook
- 2.2.3. Modalities outlook
- 2.2.4. End use outlook
- 2.2.5. Regional outlook
- 2.3. Competitive Insights
Chapter 3. AI in Medical Imaging Market Variables, Trends & Scope
- 3.1. Market Lineage Outlook
- 3.1.1. Parent market outlook
- 3.1.2. Related/ancillary market outlook
- 3.2. Market Dynamics
- 3.2.1. Market driver analysis
- 3.2.2. Market restraint analysis
- 3.3. AI in Medical Imaging Market Analysis Tools
- 3.3.1. Industry Analysis - Porter's
- 3.3.1.1. Supplier power
- 3.3.1.2. Buyer power
- 3.3.1.3. Substitution threat
- 3.3.1.4. Threat of new entrant
- 3.3.1.5. Competitive rivalry
- 3.3.2. PESTEL Analysis
- 3.3.2.1. Political landscape
- 3.3.2.2. Technological landscape
- 3.3.2.3. Economic landscape
- 3.3.3. COVID-19 Impact
Chapter 4. AI in Medical Imaging Market: Technology Estimates & Trend Analysis
- 4.1. Technology Market Share, 2023 & 2030
- 4.2. Segment Dashboard
- 4.3. Global AI in Medical Imaging Market by Technology Outlook
- 4.4. Deep Learning
- 4.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.5. Natural Language Processing (NLP)
- 4.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 4.6. Others
- 4.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 5. AI in Medical Imaging Market: Application Estimates & Trend Analysis
- 5.1. Application Market Share, 2023 & 2030
- 5.2. Segment Dashboard
- 5.3. Global AI in Medical Imaging Market by Application Outlook
- 5.4. Neurology
- 5.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.5. Respiratory and Pulmonary
- 5.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.6. Cardiology
- 5.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.7. Breast Screening
- 5.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.8. Orthopedics
- 5.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 5.9. Others
- 5.9.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 6. AI in Medical Imaging Market: Modalities Estimates & Trend Analysis
- 6.1. Modalities Market Share, 2023 & 2030
- 6.2. Segment Dashboard
- 6.3. Global AI in Medical Imaging Market by Modalities Outlook
- 6.4. CT-Scan
- 6.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.5. MRI
- 6.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.6. X-rays
- 6.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.7. Ultrasound
- 6.7.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 6.8. Nuclear Imaging
- 6.8.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 7. AI in Medical Imaging Market: End Use Estimates & Trend Analysis
- 7.1. End Use Market Share, 2023 & 2030
- 7.2. Segment Dashboard
- 7.3. Global AI in Medical Imaging Market Modalities Outlook
- 7.4. Hospitals
- 7.4.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 7.5. Diagnostic Imaging Centers
- 7.5.1. Market estimates and forecast 2018 to 2030 (USD Million)
- 7.6. Others
- 7.6.1. Market estimates and forecast 2018 to 2030 (USD Million)
Chapter 8. AI in Medical Imaging Market: Regional Estimates & Trend Analysis, By Technology, By Application, By Modalities, End Use, By AI-Powered AI in Medical Imaging
- 8.1. Regional Market Share Analysis, 2023 & 2030
- 8.2. Regional Market Dashboard
- 8.3. Global Regional Market Snapshot
- 8.4. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
- 8.5. North America
- 8.5.1. U.S.
- 8.5.1.1. Key country dynamics
- 8.5.1.2. Regulatory framework/ reimbursement structure
- 8.5.1.3. Competitive scenario
- 8.5.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.2. Canada
- 8.5.2.1. Key country dynamics
- 8.5.2.2. Regulatory framework/ reimbursement structure
- 8.5.2.3. Competitive scenario
- 8.5.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
- 8.5.3. Mexico
- 8.5.3.1. Key country dynamics
- 8.5.3.2. Regulatory framework/ reimbursement structure
- 8.5.3.3. Competitive scenario
- 8.5.3.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6. Europe
- 8.6.1. UK
- 8.6.1.1. Key country dynamics
- 8.6.1.2. Regulatory framework/ reimbursement structure
- 8.6.1.3. Competitive scenario
- 8.6.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.2. Germany
- 8.6.2.1. Key country dynamics
- 8.6.2.2. Regulatory framework/ reimbursement structure
- 8.6.2.3. Competitive scenario
- 8.6.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.3. France
- 8.6.3.1. Key country dynamics
- 8.6.3.2. Regulatory framework/ reimbursement structure
- 8.6.3.3. Competitive scenario
- 8.6.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.4. Italy
- 8.6.4.1. Key country dynamics
- 8.6.4.2. Regulatory framework/ reimbursement structure
- 8.6.4.3. Competitive scenario
- 8.6.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.5. Spain
- 8.6.5.1. Key country dynamics
- 8.6.5.2. Regulatory framework/ reimbursement structure
- 8.6.5.3. Competitive scenario
- 8.6.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.6. Norway
- 8.6.6.1. Key country dynamics
- 8.6.6.2. Regulatory framework/ reimbursement structure
- 8.6.6.3. Competitive scenario
- 8.6.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.7. Sweden
- 8.6.7.1. Key country dynamics
- 8.6.7.2. Regulatory framework/ reimbursement structure
- 8.6.7.3. Competitive scenario
- 8.6.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
- 8.6.8. Denmark
- 8.6.8.1. Key country dynamics
- 8.6.8.2. Regulatory framework/ reimbursement structure
- 8.6.8.3. Competitive scenario
- 8.6.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7. Asia Pacific
- 8.7.1. Japan
- 8.7.1.1. Key country dynamics
- 8.7.1.2. Regulatory framework/ reimbursement structure
- 8.7.1.3. Competitive scenario
- 8.7.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.2. China
- 8.7.2.1. Key country dynamics
- 8.7.2.2. Regulatory framework/ reimbursement structure
- 8.7.2.3. Competitive scenario
- 8.7.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.3. India
- 8.7.3.1. Key country dynamics
- 8.7.3.2. Regulatory framework/ reimbursement structure
- 8.7.3.3. Competitive scenario
- 8.7.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.4. Australia
- 8.7.4.1. Key country dynamics
- 8.7.4.2. Regulatory framework/ reimbursement structure
- 8.7.4.3. Competitive scenario
- 8.7.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.5. South Korea
- 8.7.5.1. Key country dynamics
- 8.7.5.2. Regulatory framework/ reimbursement structure
- 8.7.5.3. Competitive scenario
- 8.7.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
- 8.7.6. Thailand
- 8.7.6.1. Key country dynamics
- 8.7.6.2. Regulatory framework/ reimbursement structure
- 8.7.6.3. Competitive scenario
- 8.7.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8. Latin America
- 8.8.1. Brazil
- 8.8.1.1. Key country dynamics
- 8.8.1.2. Regulatory framework/ reimbursement structure
- 8.8.1.3. Competitive scenario
- 8.8.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
- 8.8.2. Argentina
- 8.8.2.1. Key country dynamics
- 8.8.2.2. Regulatory framework/ reimbursement structure
- 8.8.2.3. Competitive scenario
- 8.8.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9. MEA
- 8.9.1. South Africa
- 8.9.1.1. Key country dynamics
- 8.9.1.2. Regulatory framework/ reimbursement structure
- 8.9.1.3. Competitive scenario
- 8.9.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.2. Saudi Arabia
- 8.9.2.1. Key country dynamics
- 8.9.2.2. Regulatory framework/ reimbursement structure
- 8.9.2.3. Competitive scenario
- 8.9.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.3. UAE
- 8.9.3.1. Key country dynamics
- 8.9.3.2. Regulatory framework/ reimbursement structure
- 8.9.3.3. Competitive scenario
- 8.9.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
- 8.9.4. Kuwait
- 8.9.4.1. Key country dynamics
- 8.9.4.2. Regulatory framework/ reimbursement structure
- 8.9.4.3. Competitive scenario
- 8.9.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
Chapter 9. Competitive Landscape
- 9.1. Recent Developments & Impact Analysis, By Key Market Participants
- 9.2. Company/Competition Categorization
- 9.2.1. Innovators
- 9.2.2. List of key distributors and channel partners
- 9.2.3. Key customers
- 9.2.4. Key company market share analysis, 2023
- 9.2.5. GE Healthcare
- 9.2.5.1. Company overview
- 9.2.5.2. Financial performance
- 9.2.5.3. Product benchmarking
- 9.2.5.4. Strategic initiatives
- 9.2.6. Microsoft
- 9.2.6.1. Company overview
- 9.2.6.2. Financial performance
- 9.2.6.3. Product benchmarking
- 9.2.6.4. Strategic initiatives
- 9.2.7. Digital Diagnostics Inc.
- 9.2.7.1. Company overview
- 9.2.7.2. Financial performance
- 9.2.7.3. Product benchmarking
- 9.2.7.4. Strategic initiatives
- 9.2.8. Tempus
- 9.2.8.1. Company overview
- 9.2.8.2. Financial performance
- 9.2.8.3. Product benchmarking
- 9.2.8.4. Strategic initiatives
- 9.2.9. Butterfly Network Inc.
- 9.2.9.1. Company overview
- 9.2.9.2. Financial performance
- 9.2.9.3. Product benchmarking
- 9.2.9.4. Strategic initiatives
- 9.2.10. Advanced Micro Devices, Inc.
- 9.2.10.1. Company overview
- 9.2.10.2. Financial performance
- 9.2.10.3. Product benchmarking
- 9.2.10.4. Strategic initiatives
- 9.2.11. Heartflow Inc.
- 9.2.11.1. Company overview
- 9.2.11.2. Financial performance
- 9.2.11.3. Product benchmarking
- 9.2.11.4. Strategic initiatives
- 9.2.12. Enlitic, Inc.
- 9.2.12.1. Company overview
- 9.2.12.2. Financial performance
- 9.2.12.3. Product benchmarking
- 9.2.12.4. Strategic initiatives
- 9.2.13. Canon Medical Systems, Inc.
- 9.2.13.1. Company overview
- 9.2.13.2. Financial performance
- 9.2.13.3. Product benchmarking
- 9.2.13.4. Strategic initiatives
- 9.2.14. Viz.ai, Inc.
- 9.2.14.1. Company overview
- 9.2.14.2. Financial performance
- 9.2.14.3. Product benchmarking
- 9.2.14.4. Strategic initiatives
- 9.2.15. EchoNous, Inc.
- 9.2.15.1. Company overview
- 9.2.15.2. Financial performance
- 9.2.15.3. Product benchmarking
- 9.2.15.4. Strategic initiatives
- 9.2.16. HeartVista, Inc.
- 9.2.16.1. Company overview
- 9.2.16.2. Financial performance
- 9.2.16.3. Product benchmarking
- 9.2.16.4. Strategic initiatives
- 9.2.17. Exo Imaging, Inc.
- 9.2.17.1. Company overview
- 9.2.17.2. Financial performance
- 9.2.17.3. Product benchmarking
- 9.2.17.4. Strategic initiatives
- 9.2.18. NANO-X IMAGING LTD
- 9.2.18.1. Company overview
- 9.2.18.2. Financial performance
- 9.2.18.3. Product benchmarking
- 9.2.18.4. Strategic initiatives
°ü·ÃÀÚ·á